1. Home
  2. DNLI vs HURN Comparison

DNLI vs HURN Comparison

Compare DNLI & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • HURN
  • Stock Information
  • Founded
  • DNLI 2013
  • HURN 2002
  • Country
  • DNLI United States
  • HURN United States
  • Employees
  • DNLI N/A
  • HURN N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • HURN Professional Services
  • Sector
  • DNLI Health Care
  • HURN Consumer Discretionary
  • Exchange
  • DNLI Nasdaq
  • HURN Nasdaq
  • Market Cap
  • DNLI 2.5B
  • HURN 2.8B
  • IPO Year
  • DNLI 2017
  • HURN 2004
  • Fundamental
  • Price
  • DNLI $19.09
  • HURN $164.26
  • Analyst Decision
  • DNLI Strong Buy
  • HURN Strong Buy
  • Analyst Count
  • DNLI 13
  • HURN 4
  • Target Price
  • DNLI $32.64
  • HURN $190.25
  • AVG Volume (30 Days)
  • DNLI 1.4M
  • HURN 208.7K
  • Earning Date
  • DNLI 11-06-2025
  • HURN 10-28-2025
  • Dividend Yield
  • DNLI N/A
  • HURN N/A
  • EPS Growth
  • DNLI N/A
  • HURN 32.32
  • EPS
  • DNLI N/A
  • HURN 5.98
  • Revenue
  • DNLI N/A
  • HURN $1,618,977,000.00
  • Revenue This Year
  • DNLI N/A
  • HURN $14.19
  • Revenue Next Year
  • DNLI $94,232.03
  • HURN $9.49
  • P/E Ratio
  • DNLI N/A
  • HURN $27.58
  • Revenue Growth
  • DNLI N/A
  • HURN 12.67
  • 52 Week Low
  • DNLI $10.57
  • HURN $118.25
  • 52 Week High
  • DNLI $26.18
  • HURN $174.26
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 69.43
  • HURN 56.26
  • Support Level
  • DNLI $16.85
  • HURN $160.25
  • Resistance Level
  • DNLI $18.21
  • HURN $166.74
  • Average True Range (ATR)
  • DNLI 1.17
  • HURN 4.87
  • MACD
  • DNLI 0.23
  • HURN -0.86
  • Stochastic Oscillator
  • DNLI 90.65
  • HURN 50.58

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

Share on Social Networks: